30mg vial with 3ml bac water included
Quanta Pharma Tirzepatide 30 mg is a dual agonist peptide that activates both GLP-1 and GIP receptors. It is studied for its role in regulating insulin and glucagon activity, with research interest in its effects on glycaemic control, appetite signalling, and weight-related outcomes. Laboratory analysis reports a purity of 99.68%.
Research focus includes:
Dual incretin activity — engages GLP-1 and GIP receptor pathways in metabolic research
Glycaemic regulation — investigated for effects on insulin secretion and glucagon suppression
Appetite signalling — studied for influence on hunger and satiety mechanisms
Body composition — explored in relation to weight and fat mass changes
Pharmacokinetics — characterised by an extended half-life supporting weekly research protocols
